{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"51"}]}],"title":"Participants with SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"91"}]}],"title":"Participants with ≥ 1 treatment emergent NSAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.","groups":[{"description":"Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG000","title":"IMC-1121B (Ramucirumab)"},{"description":"Participants received placebo by intravenous infusion every 2 weeks plus best supportive care as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel were blinded as to assignment to active therapy versus placebo, the volume of placebo administered was calculated as if it were active product with a dose of 8 mg/kg. Treatment continued until there was evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Safety Population: All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Randomization up to 18 months","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}